Advice
in the absence of a submission from the holder of the marketing authorisation:
encorafenib (Braftovi®) is not recommended for use within NHSScotland.
Indication under review: in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice285KB (PDF)
Medicine details
- Medicine name:
- encorafenib (Braftovi®)
- SMC ID:
- SMC2865
- Indication:
In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 September 2025